Breast Cancer: Role of Early Detection, Treatment and Prevention

Principal Investigator: Sandra Lee (current PI) / Marvin Zelen (previous PI)
Institution: Dana-Farber Cancer Institute
Grant Number: 2U01CA088270-05

Awarded under CA-05-018
Originally funded under CA-99-013 (view abstract)

Abstract: The major goals of this proposal are to apply the stochastic model developed earlier to breast cancer issues associated with the US population. Among the issues which will be studied are: estimating the US breast cancer mortality for the period 2005-2020; investigate mortality for sub-populations (e.g., African-American, uninsured population and various scenarios); continue investigations of optimal screening schedules; investigate the role of the underreporting in SEER of invasive breast cancer following ductal carcinoma in situ (DCIS); investigate the influence on mortality if the number of women taking tamoxifen or reloxifene as a preventive agent is increased; develop a public Web site (a) which will allow investigators to make use of our theoretical breast cancer model and (b) to communicate to the general public the breast cancer predicted mortality and false positive rate for any screening program.

Awarded under CA-99-013

Abstract: The major goals of this proposal are to develop and extend statistical models which are important in predicting the future incidence and mortality associated with breast cancer in the United States. The diagnosis, treatment and prevention of female breast cancer has been rapidly changing in the decade and shows every evidence of continuing to change. Our main thrust will be to estimate the impact of interventions on national statistics. The interventions will not only reflect current health behavior practice, but will reflect various scenarios if public health practices were to change. Among the problems which will be considered are (1) to evaluate the relation between early detection and eventual mortality which considers competing risks; (2) to predict the changing incidence patterns if more women participate in routine screening programs; (3) to compare the trade-offs pertaining to both benefit and cost between optimal screening programs and recommended policies; (4) to develop optimal screening programs for high risk sub-populations; (5) to estimate the change in mortality if modern cancer treatment was routinely given to a higher proportion of the population; (6) to use the Eastern Cooperative Oncology Group (ECOG) and the Harvard Pilgrim Health Plan as a resource to gather data on diagnosis and staging currently not available; (7) to investigate screening policies and their benefit for younger women; (8) to estimate the impact of improved methods of diagnosis on incidence and mortality.